Vascular endothelial growth factor (VEGF) receptor 3 (VEGFR3), a receptor tyrosine kinase encoded by the FLT4 gene, plays a significant role in the morphogenesis and maintenance of lymphatic vessels. Under both normal and pathologic conditions, VEGF-C and VEGF-D bind VEGFR3 on the surface of lymphatic endothelial cells (LECs) and induce lymphatic proliferation, migration, and survival by activating intracellular PI3K-Akt and MAPK-ERK signaling pathways. Impaired lymphatic function and VEGFR3 signaling has been linked with a myriad of commonly encountered clinical conditions. This review provides a brief overview of intracellular VEGFR3 signaling in LECs and explores examples of dysregulated VEGFR3 signaling in various disease states, including (1) lymphedema, (2) tumor growth and metastasis, (3) obesity and metabolic syndrome, (4) organ transplant rejection, and (5) autoimmune disorders. A more complete understanding of the molecular mechanisms underlying the lymphatic pathology of each disease will allow for the development of novel strategies to treat these chronic and often debilitating illnesses.
13 June 2024 in Journal of Investigative Dermatology
Keratinocytes, once viewed as inert epidermal scaffolds, are now recognized as active participants in the cutaneous immunity. They orchestrate local immune responses by releasing cytokines, chemokines, and alarmins that shape innate and adaptive inflammation. Dysregulated keratinocyte-immune interactions underline chronic inflammatory skin disorders, such as atopic dermatitis, psoriasis, and cutaneous lupus erythematosus. More recently, keratinocytes have been identified as key contributors to secondary lymphedema, a chronic inflammatory and fibrotic condition historically attributed to lymphatic dysfunction. This review revises our understanding of keratinocytes as immunomodulatory cells, while focusing primarily on their emerging role in the pathogenesis of secondary lymphedema. We highlight and appraise recent evidence that lymphatic stasis reprograms keratinocyte differentiation, induces type 2 helper T cells-skewed inflammatory responses, and perpetuates chronic inflammation and fibrosis. Understanding this keratinocyte-immune-lymphatic axis may unveil novel therapeutic targets beyond traditional lymphangiogenic approaches.
Background: The insertion of large bore cannulas into the femoral vessels for venous-arterial extracorporeal membrane oxygenation (VA-ECMO) administration has been associated with significant acute and chronic wound complications in patients with significant medical and surgical comorbidities, including vessel exposure and lymphocele development. In this series, we report our experience using muscle flap reconstruction in the management of post-ECMO groin wounds, with particular emphasis on groin lymphocele. Methods: VA-ECMO patients at a high-acuity cardiac referral center who developed groin cannulation site complications requiring muscle flap closure were included for retrospective review. Preoperative, perioperative, and postoperative factors were analyzed. Results: Fifteen patients were included. The most common comorbidities were hypertension (66.7%), diabetes (46.7%), and renal failure (60.0%). Eight (53.3%) patients were immunosuppressed. The most frequent indications for surgery were groin lymphocele (n = 8, 53.3%) and exposed femoral vessels (n = 7, 46.7%). Median time from ECMO decannulation to reconstruction was 49.0 days. Most reconstructions were performed using a rectus femoris flap (n = 13, 86.7%). Two (13.3%) shallow wounds were covered with a sartorius muscle flap. Intraoperative cultures were positive in 9 (60.0%) patients. Seven (46.7%) patients experienced complications, including hematoma (n = 5), dehiscence (n = 1), recipient site infection (n = 1), and donor site infection (n = 1). In both groups, there were no cases involving lymphocele recurrence following reconstruction. There were no flap-specific complications and no cases of amputation. Four patients died within 1 year from septic shock (n = 3) and heart failure (n = 1). Conclusions: We report successful reconstruction in the majority of patients. In particular, muscle flap reconstruction is a useful technique for addressing ECMO-associated lymphocele development and recurrence. Future studies are needed to determine ideal timing of reconstruction and if early plastic surgeon involvement can reduce morbidity and mortality of these difficult to treat infections.